TEVA - Another big turnaround bottom play idea is TEVA. Like SRCL it's a great company that has been cut in half since 2015 (70 to under 35), but will almost certainly recover over time (Teva is the world's largest generic drug company).
With TEVA, to find key support (30) you have to go all the way back to 2006, and then the next support is in the mid 20s (from 2004). At the current 33 it looks like a good time to start accumulating.
I figure they'll be cutting their dividend at some point (currently just over 4%), and they'll have to continue to reduce debt from their big acquisition of Allergan's generic business in 2015, and there will be continued uncertainty over their big MS drug Copaxone. But longer term, Teva will remain the 800 lb gorilla in the generic drug sector.
